NASDAQ:IDXX - IDEXX Laboratories Stock Price, Forecast & News

IDEXX Laboratories trades on the NASDAQ under the ticker symbol "IDXX."

IDEXX Laboratories, Inc. (NASDAQ:IDXX) announced its quarterly earnings results on Thursday, October, 31st. The company reported $1.24 earnings per share for the quarter, beating analysts' consensus estimates of $1.14 by $0.10. The business earned $605.30 million during the quarter, compared to analysts' expectations of $597.09 million. IDEXX Laboratories had a return on equity of 405.71% and a net margin of 17.99%. The business's revenue for the quarter was up 11.0% on a year-over-year basis. During the same quarter last year, the business posted $1.05 earnings per share. View IDEXX Laboratories' Earnings History.

IDEXX Laboratories is scheduled to release their next quarterly earnings announcement on Friday, January 31st 2020. View Earnings Estimates for IDEXX Laboratories.

IDEXX Laboratories will be holding an earnings conference call on Friday, January 31st at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

IDEXX Laboratories issued an update on its FY20 earnings guidance on Thursday, October, 31st. The company provided earnings per share (EPS) guidance of $5.30-5.46 for the period, compared to the Thomson Reuters consensus EPS estimate of $5.56. The company issued revenue guidance of $2.61-2.65 billion, compared to the consensus revenue estimate of $2.63 billion.

6 brokerages have issued 1 year price objectives for IDEXX Laboratories' shares. Their forecasts range from $277.00 to $310.00. On average, they expect IDEXX Laboratories' share price to reach $293.33 in the next year. This suggests a possible upside of 5.8% from the stock's current price. View Analyst Price Targets for IDEXX Laboratories.

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for IDEXX Laboratories in the last year. There are currently 1 hold rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for IDEXX Laboratories.

Press coverage about IDXX stock has been trending somewhat negative this week, according to InfoTrie Sentiment Analysis. The research group identifies negative and positive news coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. IDEXX Laboratories earned a news impact score of -1.4 on InfoTrie's scale. They also gave news headlines about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the stock's share price in the near future. View News Stories for IDEXX Laboratories.

Some companies that are related to IDEXX Laboratories include Abbott Laboratories (ABT), Medtronic (MDT), Stryker (SYK), Becton Dickinson and (BDX), Intuitive Surgical (ISRG), Boston Scientific (BSX), Edwards Lifesciences (EW), Baxter International (BAX), ResMed (RMD), DexCom (DXCM), Teleflex (TFX), Hologic (HOLX), Varian Medical Systems (VAR), Steris (STE) and Insulet (PODD).

Based on aggregate information from My MarketBeat watchlists, some companies that other IDEXX Laboratories investors own include NVIDIA (NVDA), Paypal (PYPL), Netflix (NFLX), Alibaba Group (BABA), Adobe (ADBE), Mastercard (MA), Home Depot (HD), Intuitive Surgical (ISRG), Walt Disney (DIS) and Micron Technology (MU).

IDEXX Laboratories' stock is owned by a number of of institutional and retail investors. Top institutional investors include California Public Employees Retirement System (0.24%), Welch & Forbes LLC (0.21%), Loring Wolcott & Coolidge Fiduciary Advisors LLP MA (0.17%), New York State Teachers Retirement System (0.17%), Howland Capital Management LLC (0.15%) and Davis R M Inc. (0.14%). Company insiders that own IDEXX Laboratories stock include Brian P Mckeon, Bruce L Claflin, Daniel M Junius, Giovani Twigge, Jacqueline Studer, Jay Mazelsky, Jonathan W Ayers, Lawrence D Kingsley, M Anne Szostak, Michael Lane, Rebecca M Henderson, Sophie V Vandebroek and William T End. View Institutional Ownership Trends for IDEXX Laboratories.

IDXX stock was sold by a variety of institutional investors in the last quarter, including Tocqueville Asset Management L.P., Meag Munich Ergo Kapitalanlagegesellschaft MBH, DNB Asset Management AS, First Hawaiian Bank, Davis R M Inc., Cribstone Capital Management LLC, State of Alaska Department of Revenue and Calamos Wealth Management LLC. Company insiders that have sold IDEXX Laboratories company stock in the last year include Brian P Mckeon, Giovani Twigge, Jacqueline Studer, Jay Mazelsky, Jonathan W Ayers, M Anne Szostak, Michael Lane, Rebecca M Henderson and Sophie V Vandebroek. View Insider Buying and Selling for IDEXX Laboratories.

IDXX stock was purchased by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A., Mckinley Capital Management LLC Delaware, Johanson Financial Advisors Inc., Aurora Investment Managers LLC., Pensionfund DSM Netherlands, Chapman Investment Management LLC, Ambassador Advisors LLC and Pensionfund Sabic. Company insiders that have bought IDEXX Laboratories stock in the last two years include Bruce L Claflin and Lawrence D Kingsley. View Insider Buying and Selling for IDEXX Laboratories.

Shares of IDXX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of IDXX stock can currently be purchased for approximately $277.31.

IDEXX Laboratories has a market capitalization of $23.79 billion and generates $2.21 billion in revenue each year. The company earns $377.03 million in net income (profit) each year or $4.26 on an earnings per share basis. IDEXX Laboratories employs 8,377 workers across the globe.View Additional Information About IDEXX Laboratories.

The official website for IDEXX Laboratories is http://www.idexx.com/.

IDEXX Laboratories' mailing address is ONE IDEXX DRIVE, WESTBROOK ME, 04092. The company can be reached via phone at 207-556-0300 or via email at [email protected]